Bristol-Myers Squibb Q3 Earnings Review: Despite Today's Gains, I See Trouble Ahead

Group 1 - The article discusses the ongoing decline in the share price of Bristol-Myers Squibb Company (BMY) and its deteriorating long-term prospects in the biotech and pharmaceutical sectors [1] - The author, Edmund Ingham, is a biotech consultant with over 5 years of experience covering the industry and has produced detailed reports on more than 1,000 companies [1] - The Haggerston BioHealth investing group provides insights for both novice and experienced biotech investors, including catalysts to watch, buy and sell ratings, and financial forecasts for major pharmaceutical companies [1]